Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

North America Automated and Closed Cell Therapy Processing Systems Market Size and Forecast, 2026-2033 | $2.6 Billion Opportunity by 2032 as CAR-T and GMP Automation Accelerate

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a key player in the North America Automated and Closed Cell Therapy Processing Systems Market, indicating their involvement in this growing sector. The article does not provide specific sentiment towards the company's performance. MRK Merck KGaA is identified as a company within the scope of the North America Automated and Closed Cell Therapy Processing Systems Market report. The article does not provide specific performance sentiment or details for Merck KGaA.

North America Automated and Closed Cell Therapy Processing Systems Market Size and Forecast, 2026-2033 | $2.6 Billion Opportunity by 2032 as CAR-T and GMP Automation Accelerate Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "North America Automated and Closed Cell Therapy Processing Systems Market Size, Share & Industry Analysis Report by Type, Scale, Workflow, Country Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The North America Automated And Closed Cell Therapy Processing Systems Market is projected to reach USD 2.6 billion by 2032, expanding at a CAGR of 19.5% during 2026-2033. Growth is being driven by the transition from manual, open, and labor-intensive manufacturing workflows to automated platforms that provide stronger process control, aseptic operation, traceability, scalability, and GMP compliance.

Increasing development and commercialization of CAR-T therapies, stem cell treatments, regenerative medicine, and personalized therapies are accelerating demand for closed cell therapy processing systems. Biotechnology companies, manufacturers, CDMOs, hospitals, and research institutes are adopting these platforms to reduce contamination risk, limit operator intervention, improve cell viability, and maintain consistency across clinical and commercial production.

Market expansion is also supported by growing cell and gene therapy pipelines, strict regulatory requirements, and rising investment in advanced therapy manufacturing. Key technology trends include modular platforms, single-use technologies, AI-enabled process monitoring, electronic batch records, real-time analytics, and integrated systems for separation, expansion, washing, fill-finish, and cryopreservation.

Type Outlook

By Type, the market is segmented into Non Stem Cell Therapy and Stem Cell Therapy. Non Stem Cell Therapy dominated the market in 2025 and is expected to retain its leading position through 2033. The segment is projected to reach USD 1.5 billion by 2032, registering a CAGR of 19.1 % during the forecast period.

Growth in Non Stem Cell Therapy is supported by the commercialization of CAR-T, TCR-based therapies, NK cell therapies, and other immune cell-based products. These applications require precise and reproducible processes for cell isolation, activation, genetic modification, expansion, washing, formulation, and final preparation. Automated closed systems enhance consistency across patient-specific and donor-derived manufacturing workflows.

The Stem Cell Therapy segment is expected to grow at a CAGR of 20% during 2026-2033. Adoption is increasing across regenerative medicine research, clinical trials, tissue repair, autoimmune conditions, neurological disorders, and orthopedic applications. Automated platforms support isolation, culture expansion, differentiation, harvesting, and cryopreservation while protecting cell viability and process integrity.

Scale Outlook

By Scale, the market is divided into Pre-Commercial / R&D Scale and Commercial Scale. Pre-Commercial / R&D Scale led the market in 2025 and is forecast to remain dominant through 2033, reaching USD 1.9 billion by 2032 at a CAGR of 19.3 %.

This segment benefits from the large number of cell therapy programs in discovery, translational research, process development, and clinical testing. Academic centers, biotechnology startups, hospitals, and CDMOs require flexible systems for small-batch production, protocol optimization, early-stage validation, and clinical material manufacturing.

Commercial Scale is projected to record a CAGR of 20% during 2026-2033 as more therapies approach regulatory approval and market launch. Demand is rising for high-throughput, standardized, and GMP-compliant platforms that strengthen traceability, batch consistency, process analytics, and manufacturing efficiency while reducing labor dependency.

Workflow Outlook

By Workflow, the market includes Separation, Expansion, Apheresis, Fill-Finish, Cryopreservation, and Other Workflow. Separation holds the leading position because cell isolation is critical to therapeutic product quality. Automated closed separation systems improve purity, viability, and consistency when processing cells from blood, bone marrow, and other biological materials.

Expansion platforms enable controlled and scalable cell growth across autologous and allogeneic applications. Apheresis supports the collection of patient-derived and donor-derived cells, while Fill-Finish addresses sterile final product preparation and dosing accuracy. Cryopreservation remains essential for storage, transportation, and multi-site distribution. Other Workflow covers formulation, washing, buffer exchange, quality control preparation, and related manufacturing processes.

Country Outlook

By Country, the market is segmented into US, Canada, Mexico, and Rest of North America. The US dominated in 2025 and is expected to maintain its leadership through 2033, reaching USD 2.1 billion by 2032 at a CAGR of 18.8 %.

The US benefits from a strong cell and gene therapy pipeline, an established biotechnology sector, advanced clinical trial infrastructure, extensive CDMO capacity, regulatory maturity, and substantial investment in automated GMP-compliant production. Adoption spans CAR-T therapies, immune cell products, stem cell research, decentralized manufacturing, and digital process monitoring.

Canada is forecast to grow at a CAGR of 22.3% during 2026-2033, supported by regenerative medicine programs, academic research, CAR-T manufacturing capabilities, and investment in modular closed-system technologies. Mexico is expected to register a CAGR of 21.8%, driven by expanding biotechnology activity, clinical research, improving regulatory alignment, and greater adoption of automated processing platforms. Rest of North America contributes through specialized therapy development, cross-border collaboration, and clinical manufacturing initiatives.

Key Topics Covered

Chapter 1. North America Market

1.1 Market Overview

1.2 Key Factors Impacting Market

1.2.1 Market Drivers

1.2.2 Market Restraints

1.2.3 Market Opportunities

1.2.4 Market Challenges

1.2.5 Market Trends

1.2.6 State of Competition

1.2.7 Market Consolidation

1.2.8 Key Customer Criteria

1.3 Product Life Cycle

1.4 Segmentation By Type

1.4.1 Non Stem Cell Therapy

1.4.2 Stem Cell Therapy

1.5 Segmentation By Scale

1.5.1 Pre-Commercial / R&D Scale

1.5.2 Commercial Scale

1.6 Segmentation By Workflow

1.6.1 Separation

1.6.2 Expansion

1.6.3 Apheresis

1.6.4 Fill-Finish

1.6.5 Cryopreservation

1.6.6 Other Workflow

1.7 Segmentation By Country

1.7.1 Country Coverage

1.7.1.1 US

1.7.1.2 Canada

1.7.1.3 Mexico

1.7.1.4 Rest of North America

1.7.2 Country-Level Segmentation Framework

1.7.2.1 Segmentation By Type

1.7.2.1.1 Non Stem Cell Therapy

1.7.2.1.2 Stem Cell Therapy

1.7.2.2 Segmentation By Scale

1.7.2.2.1 Pre-Commercial / R&D Scale

1.7.2.2.2 Commercial Scale

1.7.2.3 Segmentation By Workflow

1.7.2.3.1 Separation

1.7.2.3.2 Expansion

1.7.2.3.3 Apheresis

1.7.2.3.4 Fill-Finish

1.7.2.3.5 Cryopreservation

1.7.2.3.6 Other Workflow

Chapter 2. Company Snapshots

2.1 Company Snapshot Framework

2.1.1 Business Overview

2.1.2 Key Information

2.1.3 Company Focus on Automated and Closed Cell Therapy Processing Systems Market

2.1.4 Strategic Insights

2.1.5 Strategy Deployed

2.1.6 Product & Service Portfolio

2.1.7 Representative Products / Services

2.1.8 Capability Overview

2.1.9 Technology & Innovation Focus

2.1.10 SWOT Analysis

2.1.11 Customers / End Users

2.1.12 Competitive Positioning

2.1.13 Key Differentiators

2.1.14 Portfolio Matrix

2.1.15 Analyst View

2.1.16 Future Outlook

2.2 Companies Covered

2.2.1 Thermo Fisher Scientific Inc.

2.2.2 Cytiva

2.2.3 Sartorius AG

2.2.4 Miltenyi Biotec B.V. & Co. KG

2.2.5 Lonza Group AG

2.2.6 Fresenius Kabi AG

2.2.7 Terumo BCT, Inc.

2.2.8 Bio-Techne Corporation

2.2.9 Merck KGaA

2.2.10 Cellares Corporation

For more information about this report visit https://www.researchandmarkets.com/r/4l68hq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.